Natera Inc Stock
Your prediction
Natera Inc Stock
The price for the Natera Inc stock decreased slightly today. Compared to yesterday there is a change of -€1.200 (-0.510%).
Pros and Cons of Natera Inc in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
B****
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Natera Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Natera Inc | -0.510% | 0.473% | -1.599% | 88.629% | 18.731% | 446.495% | 147.513% |
| Lantheus Holdings Inc | 0.920% | -3.947% | -9.877% | 39.269% | 53.147% | 9.802% | - |
| IRadimed Corp | 2.420% | - | - | - | - | - | - |
| Orasure Tech | 1.180% | 4.268% | -11.856% | 18.750% | 66.019% | -18.182% | -63.648% |
News
Billionaire Stanley Druckenmiller's Top Holding Isn't Nvidia. Instead, It's This Under-the-Radar Stock That Wall Street Loves.
He's a retired hedge fund manager, but people still want to know what billionaire Stanley Druckenmiller is doing with his money. The answer? Investing in the medical diagnostic company Natera
Here's Billionaire Stanley Druckenmiller's Top Holding (Hint: It's Not Alphabet or Nvidia)
Your personal portfolio doesn't necessarily need to mirror a billionaire investor's holdings. But let's face it -- they manage billion-dollar portfolios for a reason.
And that's what makes Stanley
Allogene Therapeutics Q1 Earnings Call Highlights
Allogene Therapeutics (NASDAQ:ALLO) said its first quarter of 2026 was marked by early clinical progress for its lead allogeneic CAR-T programs and a
